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PERSPECTIVE

Meiotic recombination and male infertility: from basic
science to clinical reality?
Michael C Hann*, Patricio E Lau* and Helen G Tempest
Infertility is a common problem that affects approximately 15% of the population. Although many advances have been made in the
treatment of infertility, the molecular and genetic causes of male infertility remain largely elusive. This review will present a summary of
our current knowledge on the genetic origin of male infertility and the key events of male meiosis. It focuses on chromosome synapsis
and meiotic recombination and the problems that arise when errors in these processes occur, specifically meiotic arrest and
chromosome aneuploidy, the leading cause of pregnancy loss in humans. In addition, meiosis-specific candidate genes will be
discussed, including a discussion on why we have been largely unsuccessful at identifying disease-causing mutations in infertile men.
Finally clinical applications of sperm aneuploidy screening will be touched upon along with future prospective clinical tests to better
characterize male infertility in a move towards personalized medicine.
Asian Journal of Andrology (2011) 13, 212–218; doi:10.1038/aja.2011.1; published online 7 February 2011
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INTRODUCTION
Infertility is a relatively common problem in humans, estimated to
affect around one in six couples worldwide wishing to start a family1
which is similar to the incidence of diseases associated with lifestyle,
such as diabetes or hypertension.2 Fertility is an extraordinarily complex process that involves gamete formation, transport, fertilization
and implantation which is dependent on numerous pathways and
interactions. Clearly, the large number of pathways and hundreds of
genes involved in this process provides an equally large number of
opportunities for development to go awry, leading to infertility. Given
this, infertility has a diverse range of phenotypes, the etiology of which
appears to affect both males and females equally, with a relatively
equal distribution among male factors, ovarian dysfunction and tubal
factors.2 However, the large majority of cases continue to be diagnosed
as idiopathic, reflecting a poor understanding of the molecular and
genetic defects underlying infertility phenotypes.3
CURRENT MALE FERTILITY TESTING
Typically, fertility tests in men involve semen parameter analysis
utilizing strict guidelines from the World Health Organization.4
Male infertility is defined by defects and reductions in sperm count
(oligozoospermia), motility (asthenozoospermia) and morphology
(teratozoospermia) as defined by the World Health Organization.
Additionally, the semen sample is examined for the presence of other
cells, indicators of patency and function of the genital tract amongst
others.4 Despite our ability to identify semen parameter defects that
contribute to male factor infertility, the genetic and molecular basis
underlying these defects is rarely identified.

KNOWN GENETIC FACTORS ASSOCIATED WITH MALE FACTOR
INFERTILITY
Analysis of chromosome aberrations (karyotyping) is frequently
offered as part of the fertility workup. Karyotype analysis is recommended and routinely performed for couples who experience repeated
spontaneous abortions and men with oligozoospermia, even in the
absence of other clinical presentations. Karyotype abnormalities, be
they structural or numerical in nature, are observed in 0.4% of liveborns, but infertility is associated with increased levels of chromosome
aberrations5 affecting 2% of males presenting with fertility problems;
6% of oligozoospermic and 14% of non-obstructive azoospermic
(NOA) males.6 In fact, the most common genetically identifiable cause
of male factor infertility is Klinefelter syndrome, which is a condition
that arises as the result of an additional sex chromosome (47,XXY) in
the somatic karyotype.
The second most common genetic cause of male infertility is the
presence of microdeletions on the Y chromosome, which accounts
for a large proportion of azoospermia.7 Three regions on the q-arm
of the Y chromosome have been referred to as ‘azoospermia factors’
(AZFa, AZFb and AZFc proximal to distal respectively), which have
been defined as spermatogenesis loci.8 In addition, the regions
involved in the deletion can offer valuable prognostic information
(reviewed by Krausz et al.9–11). In brief, microdeletion of the entire
AZFa or AZFb regions of the Y chromosome portends an exceptionally poor prognosis for sperm retrieval, whereas the majority of
men with AZFc deletions have sperm available either within their
semen or retrievable from their testes for use in assisted reproductive
technologies.12
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Another genetic cause of male infertility involves a single gene
mutation in the cystic fibrosis transmembrane conductance regulator
gene. In approximately 80% of cases, fibrosis transmembrane conductance regulator mutations on both alleles lead to a condition known as
congenital bilateral absence of the vas deferens.13 The absence of the
vas deferens in this condition is a phenotype that prevents the normal
transport of sperm and thus leads to male infertility.13
To date it has been estimated that genetic factors including chromosome aberrations and single gene defects account for approximately 10%–15% of severe male factor infertility.14 It is inevitable
that as our understanding of genetic and molecular mechanisms of
gamete formation, transport, fertilization and implantation improves
that most, if not all male infertility will have some identifiable genetic
component. One such example includes a study that reports up to 6%
of male patients presenting to infertility clinics with a normal somatic
karyotype have been found to have meiotic alterations in their spermatogenic cells.15
OVERVIEW OF MAMMALIAN MEIOSIS
Meiosis is a specialized form of cell division that only takes place in the
gametes and is essential for the completion of spermatogenesis.
Meiosis is a critical step in gamete formation that gives rise to four
gametes with a haploid chromosome complement from a single diploid precursor cell; in essence chromosomes undergo one replication
event followed by two reduction divisions. Errors in meiotic recombination can give rise to gamete aneuploidy (presence of extra or
missing chromosomes), which is the leading cause of pregnancy loss
and developmental disabilities in humans. This review will focus on
our current understanding of errors in male meiotic recombination, in
particular how these contribute to male factor infertility, their clinical
relevance and the translation from basic science to clinical application
will be discussed when applicable.
The process of meiosis is essential for mammalian gamete formation and has been reviewed extensively elsewhere.16–19 Nevertheless
there are several key processes that take place during meiosis that are
critical for gamete formation and correct chromosome segregation,
these will be reviewed in detail along with their role in male infertility.
The vast majority of meiotic genes have been identified in yeast and
murine models which have provided strong evidence of the catastrophic effects on fertility if meiotic genes are perturbed. Such studies
have undoubtedly provided insight into male infertility and published
studies investigating meiotic genes in humans will be discussed.
MEIOTIC PROPHASE I
Perhaps the two major events during meiosis from a genetic standpoint take place during prophase I and include: (i) homologous
(maternal and paternal) chromosome pairs locate each other and
become physically connected (synapsis); and (ii) genetic exchange
(recombination) takes place ensuring genetic diversity of the species.
Both chromosome synapsis and recombination appear to play a vital
role in correct chromosome segregation by ensuring that homologous
chromosomes remain tethered together until the appropriate time.
Meiosis in males is initiated at puberty during prophase of meiosis I
when homologous chromosomes pair and synapse. Prophase I is
divided into four stages based on the morphology of the XY bivalent
and the synaptic progression of the autosomal bivalents.20 These stages
are: leptotene, zygotene, pachytene and diplotene. Programmed
double strand breaks (DSBs) are formed and marked for repair in
the leptotene stage. The zygotene stage includes homology searches
between homologous chromosomes and the initiation of synapsis.

The completion of synapsis of homologous chromosomes and the
repair of DSBs, using homologous chromosomes as templates, occurs
from mid-zygotene through to the pachytene stages. At the end of the
diplotene stage, desynapsis of homologous chromosomes begins
except for foci of reciprocal exchange, which continues forward in
meiosis as chiasmata that are essential for correct chromosome
segregation.18
The first meiotic division is reductional and separates homologous
chromosomes, producing two secondary spermatocytes. The second
meiotic division occurs immediately after the first division resulting in
an equatorial division and the separation of sister chromatids. The net
result of this process is the production of four haploid spermatids.
MEIOTIC GENE MURINE MODELS
Gene-modified mouse models have demonstrated that genetic defects
in meiotic genes can cause catastrophic reproduction failure, suggesting the possibility that reduced fertility in a proportion of males is
likely caused by defects in meiotic regulatory genes.2,18 In fact, there
are over 400 mouse models where the occurrence of aberrant reproductive phenotypes results in male infertility which is frequently
unforeseen, but quite common.17 Numerous genes have been identified in mutant mouse models and can be characterized by specific
abnormalities involving meiotic progression, chromosome pairing
and recombination.
Gene knockout models have led to the identification of key proteins
involved in chromosome synapsis and recombination enabling
immunofluorescence techniques to be developed to study meiosis
in males (Figure 1).21,22 Such meiotic studies have undoubtedly
furthered our understanding of meiosis. However, one major drawback of such studies is the requirement for testicular biopsies. Thus,
for the most part these studies are restricted to NOA and obstructive
azoospermic (OA) individuals, with vasectomy reversal and testicular
cancer patients forming control groups.

Figure 1 Example of a human pachytene spermatocyte. SCs are shown in red,
centromeres in blue and recombination foci in yellow. Indicated are: two achiasmate bivalents (including the sex body and an acrocentric bivalent) and an
example of a discontinuity in the SC (gap). SC, synaptonemal complex.
Asian Journal of Andrology
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THE ROLE OF THE SYNAPTONEMAL COMPLEX IN
CHROMOSOME SYNAPSIS AND MEIOTIC ARREST
Chromosome synapsis begins with the formation of the synaptonemal
complex (SC). The SC is composed of transversely and axially
arranged proteins (SCP1 and SCP3, respectively) that join up homologous chromosomes during prophase I in meiosis.23 Timing and
progression of SC formation is strictly organized and maintained,24,25
but occasionally, errors in SC formation occur. Chromosome synapsis
errors include the formation of splits (unpaired regions) and gaps
(discontinuities) (Figure 1).25,26 Aberrations in chromosome synapsis
frequently occur in the heterochromatic regions of chromosomes 1
and 9 and have been reported in all investigated groups (controls,
NOA and OA patients).25,27 However, a significant increase in the
percentage of cells containing unsynapsed regions have been observed
in NOA and OA men compared to controls (20, 10 and 8%, respectively).28 This clearly has important clinical ramifications as asynapsis
in pachytene may arise from a primary meiotic defect that could result
in an increased probability of atresia.29–32 High frequencies of asynapsed regions in pachytene, likely prevent the normal progression
of meiotic prophase substages. Asynapsed regions may trigger a checkpoint that leads to partial or complete spermatogenic arrest as a result
of severe meiotic defects and hence results in the NOA phenotype.33
MEIOTIC RECOMBINATION
Meiotic recombination is mechanistically responsible for providing
the physical connections that ensure proper alignment and segregation of chromosomes during cell division through the formation of
chiasmata.34 The process of meiotic recombination is essential for
fertility and integrity of the genome. During prophase I, DSBs are
induced and parental chromosomes are paired based on homologous
sequences. An intact homologous chromosome template is then used
to repair the DSBs. Homologous recombination also occurs in somatic
cells; however, in these cells, a sister chromatid is used as a template for
repair in lieu of an intact homologous chromosome. This is a key
distinction, and results in the reciprocal exchange of genetic sequences
between homologous chromosomes and a complement of alleles that
are not associated with each other on either of the parental chromosomes.18 The result of this meiotic process is the reciprocal exchange of
genetic information, creating genetic diversity.
As with SC formation, the process of meiotic recombination is
strictly controlled, both in number and localization of recombination
events. Eighty to ninety percent of cells are found to be in the pachytene stage of meiosis in control males as it is the longest phase.26,33,35,36
Comparatively, a large percentage of NOA males have been identified
as completely lacking meiotic cells (45–53%),26,33,36,37 or severely
reduced frequencies (approximately 10% versus 80–90%) due to a
partial or complete block at the zygotene stage.35 The average number
of recombinatorial events per cell in control males has been shown to
be approximately 50 through cytogenetic studies and immunofluorescence data.36,38–42 There is a significant degree of variability
between controls (13–25%) and between cells from the same individual (range: 42.5–55.3 recombination foci per cell).39–42 The majority of published studies provide evidence of a significant reduction in
recombination events per cell in NOA individuals compared to controls (40–42 versus 46–49).33,35,36 Two studies have reported no such
difference in overall recombination between NOA and controls.26,43
ABSENCE OF MEIOTIC RECOMBINATION
Achiasmate bivalents (bivalents lacking a recombination event) have
been reported in all investigated patient groups (Figure 1). The
Asian Journal of Andrology

frequency of achiasmate bivalents in NOA males has been reported
to occur in up to 29% of investigated pachytene spreads, significantly
higher than the 0.1–5% reported in controls. Studies that have karyotyped SCs by fluorescent in situ hybridization (FISH) have revealed
that chromosomes 21, 22, X and Y are the most frequently involved.
Given that the bivalents in question almost exclusively only possess
one recombinatorial event, rather than two or more as found for all
other bivalents this finding is perhaps, not unexpected.42,44,45 When
considering the sex chromosomes alone (distinguishable without
FISH), there are mixed reports; including several NOA individuals
with a complete absence of recombination in the sex body26,46 and
one report stating no significant difference between NOA and control
groups.26 It should be noted that this study does report a significant
increase in achiasmate sex bodies for individual NOA men compared
to controls.26 Achiasmate bivalents are clinically relevant as these
bivalents theoretically are unable to orientate themselves on the metaphase plate in order to ensure correct chromosome segregation in the
resultant daughter cells.33 Therefore, reduced or absent meiotic
recombination may lead to increased sperm aneuploidy frequencies,
or even spermatogenic arrest, resulting in infertility.36,47,48
MEIOTIC GENES INVESTIGATED IN INFERTILE MEN
Over 75 genes in male infertility mouse models have been identified
that when disturbed, can perturb chromosome pairing and synapsis,
recombination, aneuploidy, DNA replication and repair in spermatocytes.17 However, to date, only a handful of studies investigating
meiotic gene mutations in infertile human men have been conducted.
For most part, disease-causing mutations involved in male meiosis
have remained largely elusive with the exception of SPO11 and
SYCP3 mutations.3,49 Several other studies have investigated genes
including SYCP3, SPO11, FKBP6, BOULE, H2AX and REC8, but have
failed to identify any disease-causing mutations.3,50–57
The initiation of meiotic recombination is regulated in a large part
by the protein SPO11. The SPO11 protein is a type II topoisomerase
required for DSB formation in the leptotene stage.58 Errors in meiotic
recombination have been reported in SPO112/2 mice models, which
are infertile and have smaller gonads than wild-type or heterozygote
mice.18 Additionally, yeast SPO11 mutants show a range of phenotypes from partial loss of function, to complete loss of DSB formation.59 Both spermatocytes and oocytes from SPO112/2 mice have
been demonstrated to undergo apoptosis during pachytene and diplotene, respectively.18 Although mutations in SPO11 and its regulatory
sequences do not appear to be a common contributor to human male
infertility, when they are present, formation of DSBs appears to be
greatly affected.18 Two NOA patients (n5144) with SPO11 missense
mutations in exons 1 and 9 of the SPO11 gene and 16 single nucleotide
polymorphisms in intron regions have been identified.18 However,
Mori et al.52 did not identify any disease causing mutations in
SPO11 in 53 NOA patients.
The SYCP3 (or SCP3) gene has been shown to encode a DNAbinding protein that is involved in mediating synapsis between homologous chromosomes during meiosis and forms a key structural
component of the SC. SYCP3 has clearly been shown to result in
meiotic arrest when absent in mouse knockout models,60–62 as a result
of massive apoptotic cell death during meiotic prophase I due to SC
formation failure.62 Two azoospermic individuals (n519) with
maturation arrest have been shown to have a 1-bp deletion
(643delA) resulting in a premature stop codon and truncation of
the C-terminal, coiled coil-forming region of the SYCP3 protein.3
The resultant mutant protein demonstrated significantly reduced
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interaction with the wild-type protein in vitro and interfered with
SYCP3 fiber formation in cultured cells.3 However, two other published studies have not identified any disease-causing mutations in
SYCP3 (n558 and n522).50,55 It is of note that the patient population
recruited to these studies contained heterogeneous infertility phenotypes including azoospermia, severe oligozoospermia, Y-chromosome
microdeletions, and complete and incomplete maturation arrest.
GENOME EXPRESSION PROFILING TO IDENTIFY MEIOTIC
GENES
Perhaps the easiest manner in which we can characterize meiotic genes
is through whole-genome expression profiling using oligonucleotide
microarrays, but such gene sets often include non-meiotic genes. A
recent elegantly designed study has developed a novel strategy to
investigate meiotic-specific genes in mice and characterized a subset
of the identified gene products using reverse transcription-PCR of
RNA.2 This study utilized meiotic cells that were fractionated and
enriched by gravity sedimentation from mouse developing testis, thus
allowing the expression profiles of different enriched meiotic cells to
be investigated. This study has identified a total of 726 meiotic-specific
candidate genes that were upregulated during the leptotene/zygotene
stage. Human orthologs of these genes are potential candidates for
meiotic arrest and potentially chromosome aneuploidy.2
THE RELATIONSHIP BETWEEN CHROMOSOME ANEUPLOIDY
AND MALE INFERTILITY
The majority of men presenting with infertility are karyotypically
normal but have reduced semen parameters as defined by the World
Health Organization.4 Perhaps one of the most striking observations is
that infertile men have significantly increased sperm aneuploidy levels
(investigated by FISH analysis) compared to their fertile counterparts.
Increased sperm aneuploidy levels have been reported in infertile men
for all abnormal semen profiles (oligozoospermia, asthenozoospermia, teratozoospermia and azoospermia).63,64 This finding has
obvious clinical ramifications given the fact that aneuploidy, albeit
predominantly maternal in origin (except for the sex chromosomes),
is the leading cause of pregnancy loss and developmental disabilities in
humans.47 Increased aneuploidy frequencies in infertile men have
been reported for all investigated chromosomes. It should be noted
that the nuclear position the chromosome probe occupies and the
probe signal size has been suggested to influence the perceived levels
of aneuploidy.65 However, it is clear that certain chromosomes are
more prone to non-disjunction (chromosomes 21, 22, X and Y); with a
two- to threefold increase in aneuploidy levels for these chromosomes
compared to other chromosomes. Indirect evidence of the requirement for meiotic recombination for correct chromosome segregation
has been provided by the observation that achiasmate bivalents predominantly involve chromosomes 21, 22, X and Y; mirroring the
observation that these are most commonly observed chromosome
aneuploidies in sperm. Further evidence that achiasmate bivalents
can give rise to sperm aneuploidy has been demonstrated by the observation that the majority of 47,XXY conceptuses of paternal origin have
arisen as a result of failure of recombination between the paternal sex
chromosomes.66 Additionally, there is recent evidence of a correlation
between increased sperm aneuploidy and achiasmate bivalents in
NOA patients.26,67
The majority of aneuploidy studies in sperm from infertile men
report around a threefold increase in sperm aneuploidy levels compared to controls, with levels of up to 10-fold being reported; predominantly for severe infertility (severe oligoasthenoteratozoospermia

and azoospermia).68,69 There are a few case reports of extraordinarily
high levels of aneuploid and polyploid sperm (50–100%) in individuals with a high proportion of macrocephalic, multinucleated and
multiflagellate sperm.70–73 It perhaps counterintuitive but there is
little or no evidence to suggest that there is a preferential selection
of chromosomally normal sperm for fertilization. In fact, the threefold
increase in aneuploidy observed in sperm from infertile men, is
mirrored by a threefold increase in de novo chromosome abnormalities observed in conceptuses after intracytoplamic sperm injection
compared to the general population.74
SUMMARY
To date, only a relatively small subset of infertile human men have
been studied and reported in the literature. Despite this, we can clearly
identify meiotic abnormalities in chromosome pairing, meiotic progression and meiotic recombination in humans associated with male
infertility by immunofluorescence and FISH. Additionally, there is
emerging evidence suggesting a correlation between errors in synapsis
and recombination that lead to spermatogenic arrest and increasing
levels of aneuploidy in the gametes which has obvious clinical ramifications. Intuitively impairment of chromosome segregation will
have a major impact on the process of meiosis and therefore spermatogenesis. Two lines of evidence strongly suggest that the mechanism of action may involve aberrant chromosome synapsis and
meiotic recombination. Firstly, studies investigating meiosis in pachytene spermatocytes suggest that azoospermia is, at least in part, related
to an inadequate chromosome pairing and/or synapsis.35,67 Secondly,
reduced or absent recombination has been associated with paternally
derived XXY trisomy.75 Meiotic recombination mediates a critical
meiotic checkpoint, which ensures that all chromosomes are correctly
paired. In the absence of correct chromosome pairing, these cells are
subsequently eliminated leading to azoospermia or oligozoospermia.
However, the system is not perfect and some cells escape the meiotic
checkpoint and hence have a higher risk of aneuploidy as a result
of aberrant chromosome synapsis and/or recombination. What is
hitherto poorly understood and remains the subject of future research
is the precise mechanism(s) by which aberrant chromosome pairing
and reduced recombination occurs in infertile men.
ISSUES ASSOCIATED WITH IDENTIFYING MUTATIONS IN
HUMAN MEIOTIC GENES
The identification of disease-causing mutations in human meiotic
genes remains a potentially rich source of genetic aberrations that
may provide the basis of a variety of infertility phenotypes, particularly
for those involving spermatogenic arrest and increased sperm aneuploidy. However, to date, the identification of mutations in such meiotic genes remains largely elusive and somewhat disappointing with
reported mutations in only two genes SPO11 and SYCP3. The reasons
for this are numerous; to date, only a handful of meiotic genes in
humans have been analyzed with potentially hundreds of genes
remaining to be characterized. Thus, although a large number of genes
have been identified in mice models, we have yet to characterize many
of the genes in humans that regulate the initiation, progression and
completion of meiosis. Mutations in human meiotic genes may be
relatively rare and the patient sample size in most studies is extraordinarily small, and thus may explain the lack of identified mutations. The issue is further confounded when the large heterogeneous
etiology of infertility is considered. Mutations will probably be
restricted to a subset of patients, and problems arise as patients may
be included in a heterogeneous study group due to the unspecific
Asian Journal of Andrology
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nature of the designation of their infertility. There is clearly a requirement for an appropriate collection of well-characterized patients with
clearly defined meiotic defects to be enrolled in each study, likely only
achievable through large multicenter studies, which is associated with
its own problems. Specifically, the categorization of infertile men into
azoospermic or oligozoospermia may not be specific enough to
identify a patient group that has a truly homozygous etiology for
infertility. For example, it is likely that a mutation in a gene that causes
a complete block at leptotene will be different from one that results in a
block at zygotene or one in which some cells are capable of progressing
to pachytene for example. The issue is further confounded by the fact
that prophase I is a complicated biological process mediated by potentially hundreds of genes and perhaps by complex gene interactions.2,76,77 Researchers are also facing a major challenge applying
yeast data to humans, given that meiotic genes tend not to be orthologous. Additionally, mutations in humans are most likely to be
heterozygous mutations which will probably produce considerably
milder phenotypes than those observed in homozygous animal
models, in which mutations often encompass large parts of the gene
or complete knockouts. Heterozygous mutations will most likely not
result in the catastrophic reproductive phenotypes observed in mouse
models. Nevertheless, such mutations may produce germ cells that
have higher aneuploidy frequencies, but that are still capable of completing meiosis because of the heterozygous nature of the mutation.
Another confounding fact is that by definition male infertility mutations may in some cases arise de novo, which precludes familial linkage
analysis. However, one elegantly designed study has evaluated 172
candidate polymorphisms for associations with oligozoospermia
and NOA, and has suggested that male factor infertility is likely to
be multigenic.78 The majority of complex diseases studied to date,
have proven to be multigenic;79 this current male infertility
genome-wide association study supports this theory.78 This finding
explains why no single nucleotide polymorphism has been identified
that accounts for any particular male infertility phenotype. The
authors go on to suggest that infertility phenotypes may arise as a
result of a large number of rare variants with a small effect that in
combination are the cause of spermatogenic failure,78 thus requiring
much larger multicenter genome-wide studies perhaps involving
thousands of individuals with well-characterized male infertility phenotypes to be undertaken; which is by no means a simple task.
Additionally, structural variations within the genome such as copy
number variants may also play a role in male infertility and should
be investigated in these patient cohorts.78
CLINICAL APPLICATION OF SPERM ANEUPLOIDY SCREENING
Sperm aneuploidy studies have proven to be a valuable research tool
that has enhanced our understanding of the paternal contribution of
aneuploidy. Research thus far has shown that infertile men (in particular severe oligoasthenoteratozoospermia and azoospermic individuals) have significantly increased errors in chromosome synapsis and
meiotic recombination compared to their fertile counterparts, leading
to increased chromosome non-disjunction. Clinical testing of aneuploidy frequencies in sperm is relatively simple to achieve and has been
initiated in some clinics. However, sperm aneuploidy screening does
suffer from some drawbacks that are not insurmountable but have
precluded widespread clinical application. These have been reviewed
in detail elsewhere, but in brief include: (i) requirement to score
5–10 000 sperm; (ii) frequently only 2–5 chromosomes are tested;
(iii) the individual sperm to be used for fertility treatment cannot be
screened; therefore, it can only provide an assessment of risk; (iv) there
Asian Journal of Andrology

is a need to identify individuals who would benefit from screening; and
(v) the clinical significance of increased sperm aneuploidy still remains
unclear.21 Nevertheless, only through continued research into meiotic
recombination errors and prospective sperm aneuploidy studies will
it be possible to gain a better understanding of the clinical significance
of increased sperm aneuploidy. It is clear from the scientific literature
that several patient groups could benefit from clinical aneuploidy
screening prior to fertility treatment given the significantly higher
sperm aneuploidy frequencies observed. These include: (i)
Klinefelter syndrome patients; (ii) patients with cytogenetically visible
structural chromosome aberrations; (iii) NOA patients (should
enough sperm be available for treatment and screening); (iv) oligoasthenoteratozoospermic patients; (v) patients with a history of
unexplained recurrent pregnancy loss or repeated in vitro fertilization
or intracytoplamic sperm injection failure; and (vi) patients with
very high levels macrocephalic, multinucleated and multiflagellate
sperm.21,80–83 Performing routine sperm aneuploidy screening in
these patients will enable a more individualized risk assessment of
aneuploid offspring. For example, the genetic counseling of a
patient with low levels of sperm aneuploidy (comparable to fertile
controls) will be very different to that of an individual with 40%
aneuploid sperm. This will ultimately allow couples to make more
informed choices about their reproductive future based on their individualized risks.21
EMERGING RESEARCH IN THE FIELD OF MALE INFERTILITY
Perhaps some of the most exciting research in the field is from
emerging studies that suggest that the process of spermatogenesis
and fertilization is potentially mediated through a variety of other
mechanisms that might be associated with infertility phenotypes,
including: epigenetic modifications,84,85 ubiquitination,86,87 genome
organization perturbations,88 spermatozoal RNAs,89 proteomics,90
environmental contaminants and pharmacological agents that may
contribute to sperm DNA damage91 among others.
FUTURE CLINICAL PERSPECTIVES FOR MALE FACTOR
INFERTILITY
The research field of reproductive genetics in male infertility is striving
towards being able to offer personalized medicine to identify the
genetic and molecular basis of male infertility phenotypes. One
such example of a personalized approach was previously published
demonstrating in a small cohort of men, a significant reduction in
sperm aneuploidy levels coincident with traditional Chinese herbal
medicine treatment for male infertility.82,92 The ultimate goal has to
be the ability to offer valuable clinical prognostic options with appropriate treatment options as a result of the genetic basis of the infertility
phenotype. This clearly remains a question for basic science at present
and for the immediate future. Nevertheless, such goals have already
been achieved through the identification of Y-chromosome microdeletions in azoospermic men, for which clearly defined genotype–
phenotype correlations exist depending on the AZF region the
microdeletion encompasses.
CONCLUSION
Current semen analysis is a very limited test at best. Research suggests
that as genomic technologies advance, we are likely to see the advent of
fertility specific microarray chips that will contain genes known to be
involved in gamete formation, transport and fertilization86 along with
a battery of other tests including epigenetic and proteomic tests to
better characterize and identify the genetic basis of male infertility
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phenotypes. Unlike the current situation, this will ultimately enable
patients attending fertility clinics to be offered a comprehensive
diagnosis (rather than idiopathic infertility), along with valuable
prognostic information allowing individualized medicine and treatment options.
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